Top

Published in:

01-06-2010 | Original Article

Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study

Authors: Lale Atahan, Ferah Yıldız, Mustafa Cengiz, Bunyamin Kaplan, Metin Özkan, Gozde Yazici, Mete Gündoğ, Ayfer Haydaroğlu, Aylin F. Korcum, Meriç Şengöz, Maktav Dinçer, Müge Akmansu, Kayıhan Engin, Mutlu Hayran

Published in: Supportive Care in Cancer | Issue 6/2010

Abstract

Introduction

In this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated.

Materials and methods

Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated.

Results and conclusion

No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid.

Domchek SM, Younger J, Finkelstein DM, Seiden MW (2000) Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89:363–368. doi:10.1002/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3 CrossRefPubMed

Lipton A (2005) Management of bone metastases in breast cancer. Curr Treat Options Oncol 6:161–171. doi:10.1007/s11864-005-0023-0 CrossRefPubMed

Coleman RE (2001) Metastatic bone disease: clinical features, pathophsiology and treatment strategies. Cancer Treat Rev 27:165–176. doi:10.1053/ctrv.2000.0210 CrossRefPubMed

Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br J Cancer 55:61–66PubMed

Bates T (1992) A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 23:217–221PubMed

Maher EJ (1992) The use of palliative radiotherapy in the management of breast cancer. Eur J Cancer 28:706–710. doi:10.1016/S0959-8049(05)80131-5 CrossRefPubMed

Fleisch H (2002) Development of bisphophonates. Breast Cancer Res 4:30–34. doi:10.1186/bcr414 CrossRefPubMed

Gnant M, Mlineritsch B, Schippinger W et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840–849. doi:10.1016/S1470-2045(08)70204-3 CrossRefPubMed

Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S, American Society of Clinical Oncology (2003) 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057. doi:10.1200/JCO.2003.08.017 CrossRefPubMed

10.

Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Easton D, Austin D, Palmer SG, Yarnold JR (1986) Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6:247–255. doi:10.1016/S0167-8140(86)80191-8 CrossRefPubMed

11.

Tong D, Gillick L, Hendrickson FR (1982) The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Therapy Oncology Group. Cancer 50:893–899. doi:10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y CrossRefPubMed

12.

Madsen EL (1983) Painful bone metastases: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy × 6 versus 10 Gy × 2. Int J Radiat Oncol Biol Phys 9:1775–1779PubMed

13.

Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M (2005) Randomized trial of short- versus long- course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 11:798–804

14.

Wu JS, Wong R, Johnston M, Bezjak A, Whelan T (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605. doi:10.1016/S0360-3016(02)04147-0 PubMed

15.

van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, Leer JW (2003) Single- versus multipl- fraction radiotherapy in patients with painful bone metastases: cost-Utility analysis based on a randomized trial. J Natl Cancer Inst 95:222–229PubMedCrossRef

16.

Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD (2003) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy- A systematic rewiev of randomized trials. Clin Oncol 15:345–352. doi:10.1016/S0936-6555(03)00113-4 CrossRef

17.

Crellin AM, Marks A, Maher EJ (1989) Why don’t British radiotherapists give single fractions of radiotherapy for bone metastases. Clin Oncol 1:63–66. doi:10.1016/S0936-6555(89)80036-6 CrossRef

18.

Flanagan AM, Chambers TJ (1991) Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407–415. doi:10.1007/BF02555852 CrossRefPubMed

19.

Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(Suppl):2961–2978. doi:10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L CrossRefPubMed

20.

Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorptio in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235–242PubMed

21.

Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Mönkkönen J, Salo J, Väänänen K (2002) Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 70:40–47. doi:10.1007/s002230010047 CrossRefPubMed

22.

Fisher JE, Rodan GA, Reszka AA (2000) In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141:4793–4796. doi:10.1210/en.141.12.4793 CrossRefPubMed

23.

Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342. doi:10.1038/nature01658 CrossRefPubMed

24.

Pavlakis N, Schmidt RL, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474

25.

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735–1744. doi:10.1002/cncr.11701 CrossRefPubMed

26.

Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36–43. doi:10.1002/cncr.11892 CrossRefPubMed

27.

Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a Randomized, Placebo-Controlled Trial. J Clin Oncol 23:3314–3321. doi:10.1200/JCO.2005.05.116 CrossRefPubMed

28.

Coleman RE, Rosen LS, Gordon D, Major P, Kaminski M, Apffelstaedt J, Howell A, Chen B-L, Seaman JJ (2002) Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal–related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis. Breast Cancer Res Treat 76(suppl.):355

29.

Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphophonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459–1468PubMed

30.

Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegrin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastases. Cancer Res 61:4432–4436PubMed

31.

van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S (1996) Biphophonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698–705. doi:10.1172/JCI118841 CrossRefPubMed

32.

Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P (1997) Biphophonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890–3894PubMed

33.

Vogt U, Bielawski KP, Bosse U, Schlotter CM (2004) Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 12:1109–1114PubMed

34.

Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126–1134. doi:10.1054/bjoc.2001.1727 CrossRefPubMed

35.

Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364–371. doi:10.1002/ijc.20602 CrossRefPubMed

36.

Magnetto S, Boissier S, Delmas PD, Clezardin P (1999) Additive antitumor activities of taxoids in combination with the biphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 83:263–269. doi:10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T CrossRefPubMed

37.

Ural AU, Avcu F, Candir M, Guden M, Ozcan MA (2006) In vitro synergistic effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res 8:R52. doi:10.1186/bcr1543 CrossRefPubMed

38.

Arrington SA, Damron TA, Mann KA, Allen MJ (2008) Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and microarchitecture in a mouse model of tumor-induced osteolysis. J Surg Oncol 97:284–290. doi:10.1002/jso.20949 CrossRefPubMed

39.

Blitzer PH (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55:1468–1472. doi:10.1002/1097-0142(19850401)55:7<1468::AID-CNCR2820550708>3.0.CO;2-M CrossRefPubMed

Title: Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study
Authors: Lale Atahan
Ferah Yıldız
Mustafa Cengiz
Bunyamin Kaplan
Metin Özkan
Gozde Yazici
Mete Gündoğ
Ayfer Haydaroğlu
Aylin F. Korcum
Meriç Şengöz
Maktav Dinçer
Müge Akmansu
Kayıhan Engin
Mutlu Hayran
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 6/2010
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-009-0663-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Materials and methods

Results and conclusion

Please log in to get access to this content

Other articles of this Issue 6/2010

Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function

Perceived barriers to physical activity for colorectal cancer survivors

Sexual issues in early and late stage cancer: a review

Gustatory and olfactory function in breast cancer patients

Patients’ experience of oxygen therapy and dyspnea: a qualitative study in home palliative care

Sleep quality after initial chemotherapy for breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer